STX-6398 / Soley Therap - LARVOL DELTA

Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026 (Businesswire) - "The AACR presentation will describe the discovery and preclinical characterization of STX-6398, an oral small molecule that modulates CKAP2 and its downstream signaling pathways. Studies demonstrate selective anti-tumor activity in vitro and in vivo, with efficacy observed across preclinical models following oral administration."

Preclinical • Oncology